Article

Low-grade non-hodgkin lymphomas.

Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada.
Seminars in Radiation Onchology (impact factor: 4.03). 08/2007; 17(3):198-205. DOI:10.1016/j.semradonc.2007.02.006 pp.198-205
Source: PubMed

ABSTRACT The most common low-grade non-Hodgkin lymphomas are of B-cell origin. This review will focus on follicular lymphomas and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas. These are radiation-sensitive lymphomas. Moderate doses (30-35 Gy) for these stage I and II low-grade lymphomas result in long-term local control and possible cure. Involved-field radiation therapy is the standard approach and produces minimal morbidity. However, a significant proportion of patients relapse with systemic disease outside of radiation fields. For follicular lymphoma, this occurs in approximately 50% of patients after 15 years and for nongastric MALT lymphoma 30% to 40% after 10 years. Patients with relapsed disease are not curable with chemotherapy, but the disease often remains indolent and prolonged survival is observed. For gastric MALT lymphomas associated with Helicobacter pylori but which did not respond to antibiotic therapy, radiation treatment is indicated and almost always curative. For localized MALT lymphomas not related to microorganisms, radiation therapy is the initial standard therapy regardless of anatomic location. Patients with stage III and IV low-grade lymphoma and local symptoms are often successfully palliated with a low dose regimen of 2 x 2 Gy (total dose 4 Gy).

0 0
 · 
1 Bookmark
 · 
51 Views

Keywords

common low-grade non-Hodgkin lymphomas
 
extranodal marginal zone lymphomas
 
gastric MALT lymphomas
 
Helicobacter pylori
 
II low-grade lymphomas result
 
Involved-field radiation therapy
 
IV low-grade lymphoma
 
localized MALT lymphomas
 
low dose regimen
 
Moderate doses
 
mucosa-associated lymphoid tissue
 
nongastric MALT lymphoma 30%
 
patients
 
patients relapse
 
radiation treatment
 
relapsed disease
 
stage III
 
standard approach
 
systemic disease
 
total dose 4 Gy